Evidence Synthesis for Pharmaceutical Companies
EviMeRx provides systematic literature reviews, literature search services and evidence synthesis to pharmaceutical medical affairs, market access and regulatory teams — built to withstand HTA and regulatory scrutiny.
Pharmaceutical teams rarely need a literature review for its own sake. The review exists to support a submission, a launch, a publication or a decision, and it has to survive whatever scrutiny that endpoint brings. That changes what good looks like: the method has to be defensible, every number traceable, and the timeline has to fit the milestone it feeds.
Market access and HTA submissions
HTA bodies assess the systematic review underpinning a submission as closely as the clinical data itself — the search strategy, the exclusion reasons, the handling of heterogeneity. We build reviews to be examined that way: prospectively registered protocol, dual independent screening, documented QC, and a complete audit trail from the final evidence table back to the source publication.
Medical affairs and publication planning
Medical affairs teams use evidence synthesis to establish where a therapy sits in the literature, identify gaps worth generating data against, and support publication plans. We deliver the review and the publication-ready manuscript or congress abstract together, so the evidence and its communication are not two disconnected projects.
Regulatory and safety evidence
Comprehensive, reproducible literature searching supports regulatory documentation, benefit-risk assessment and safety reporting. The requirement here is completeness and reproducibility rather than selectivity — the search has to be defensible as exhaustive within its stated limits.
Literature search services
Not every requirement is a full systematic review. Targeted and scoping searches, surveillance updates to an existing review, and standalone search strategy development are available as discrete pieces of work — with the same documentation standards, so a scoping search can later be upgraded into a full review without starting over.
Working alongside your team
We work to client SOPs and templates where they exist, sign NDAs before project initiation, and can take on a full review end to end or a single stage of one already in progress — a protocol that needs writing, a screening backlog, or synthesis of an included set someone else assembled.